Online pain education programs for people with Crohn's disease or ulcerative colitis
Tests two online pain education programs in adults with inflammatory bowel disease and chronic pain.
Key facts
- Who runs it
- Cedars-Sinai Medical Center
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Online Pain Education for Crohn's Disease and Ulcerative Colitis
- Status
- Not yet recruiting
- People taking part
- 60 people, planned
- Started
- Oct 2026
- Expected to end
- Sept 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Empowered Relief
- Living Better with Chronic Pain
- Record updated
- 26 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Crohn's disease or ulcerative colitis who have had chronic pain for at least 3 months. They will try one of two online pain education programs.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Doctor-confirmed Crohn's disease or ulcerative colitis, with IBD-related chronic pain for at least 3 months and a NIH PROMIS Pain Interference scale T-score of 60 or higher. Medically stable: no IBD hospital stay for an acute problem in the past 3 months, and no planned IBD surgery or planned treatment step-up in the next 2 months.
- Earlier treatment
- People who take opioid medicines on a standing basis, who had cognitive behavioral therapy (CBT) aimed at chronic IBD pain, or who took oral steroids in the past 2 months cannot join.
Main reasons for not taking part
- Memory or thinking problems, or another condition that would get in the way of taking part
- Current use of standing opioid medicines
- Earlier cognitive behavioral therapy (CBT) aimed at chronic IBD pain
- Oral steroid medicines for any condition in the past 2 months
- Cannot complete questionnaires alone in English, or has no internet-enabled device
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Physician-confirmed diagnosis of Crohn's disease or ulcerative colitis
- Chronic pain (visceral and/or somatic) related to IBD for at least 3 months
- NIH PROMIS Pain Interference scale T-score ≥60
- Medically stable, defined as:; No acute IBD-related hospitalization within the past 3 months; AND; No planned IBD surgery or planned therapeutic escalation within the next 2 months, including initiation of a new advanced therapy, dose escalation or switch of advanced therapy, or corticosteroid taper
- Able to understand and complete questionnaires independently in English
- Access to an internet-enabled device for online surveys and intervention access
Who cannot take part
- Current use of standing opioid medications, given the often severe impact of opioids on GI motility and potential for pharmacological visceral hyperalgesia
- Prior participation in cognitive behavioral therapy (CBT) specifically targeting chronic IBD-related pain
- Cognitive impairment or other condition that, in the opinion of the investigators, would interfere with protocol participation
- Taken any oral steroid medications for IBD or any other condition in the past 2 months (including prednisone, prednisolone, and methylprednisolone [Medrol])
Where in United States
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Zoe Krut, MSHSNot yet recruiting
About the trial
What the trial wants to find out
Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online pain educations programs among adult patients with inflammatory bowel disease (IBD) who experience chronic pain. Each online program can be accessed on the patient's personal device, and will take up to 2 hours to complete. Clinical outcomes (pain intensity, pain interference, quality of life) will be assessed via online surveys at baseline and then weekly for 8-weeks post-treatment.
The 2 groups in the trial
- Empowered ReliefTreatment being tested
Participants randomized to the Empowered Relief arm will be scheduled to attend a 2-hour, live-online group Empowered Relief session. Empowered Relief sessions will be conducted via Zoom. Attendance of the Empowered Relief session will be monitored by study staff throughout the 2-hour session. Following the Empowered Relief session, participants in this arm will be provided with access to the 20-minute binaural audio relaxation app the that accompanies the Empowered Relief program and promotes calm through brainwave entrainment. Participants will be instructed to utilize the binaural audio app daily for the 8-weeks following the completion of the Empowered Relief session.
- Living Better with Chronic PainExisting treatment, for comparison
Living Better with Chronic Pain provides education on: (i) chronic pain mechanisms, (ii) nutrition and weight management, (iii) physical activity, (iv) working with healthcare providers, (v) informed treatment decisions, and (vi) medication safety. Participants randomized to the Living Better with Chronic Pain arm will be sent a link to access the \~1-hour online recording. Completion of the entire Living Better with Chronic Pain video will be monitored and confirmed by study staff.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Randomized Controlled Trial of Online Pain Education Programs for Inflammatory Bowel Disease
- Plain-language title
- Online pain education programs for people with Crohn's disease or ulcerative colitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 26 October 2026